Clinical Trials
4 trialsNCT01403974 2025-07-25
Phase I Trial of BI 836845 for Various Solid Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT01317420 2025-07-11
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Boehringer Ingelheim
Phase 1 Completed
NCT02145741 2025-06-19
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed